928 Subgroup analysis by chemotherapy regimen in the ENGOT-Ov41/GEICO 69-O/ANITA phase 3 trial evaluating atezolizumab combined with a platinum doublet and maintenance niraparib for late-relapsing ovarian cancer
Heitz, Florian, Pardo, Beatriz, Sabatier, Renaud, Colombo, Nicoletta, Henry, Stéphanie, Marquina, Gloria, Joly, Florence, Quindós, María, Mansi, Laura, Estévez-García, Purificación, Frenel, Jean-Sebastien, Guerra, Eva, Manso, Luis, Casado, Victoria, Sánchez-Lorenzo, Luisa, Ortega, Mª Eugenia, Duliège, Delphine, Marmé, Frederik, Martínez, Elena García, Martín, Antonio Gonzalez
Published in International journal of gynecological cancer (10.03.2024)
Published in International journal of gynecological cancer (10.03.2024)
Get full text
Journal Article
452 Primary analysis of GEICO 120/DORA, a real-world multicentre study of dostarlimab in patients with recurrent or advanced DNA mismatch repair deficient/microsatellite instability-high (DMMR/MSI-H) endometrial cancer
Gallego, Alejandro, Madariaga, Ainhoa, Estévez-García, Purificación, Albertí, Facundo, Carbó, Anna, Palacio, Isabel, Churruca, Cristina, Gálvez, Fernando, Ortega, Mª Eugenia, Murata, Paola, Manzano, Aránzazu, Masvidal, Maria, Martín-Lorente, Cristina, Hernando, Blanca, Lozano, Inmaculada, Cueva, Juan F, Garcia-Illescas, David, Falcó, Esther, Mendiola, Marta, Redondo, Andrés
Published in International journal of gynecological cancer (10.03.2024)
Published in International journal of gynecological cancer (10.03.2024)
Get full text
Journal Article